Cordis Corporation To Establish New Innovative Research Center In Silicon Valley

MIAMI, May 25 /PRNewswire-FirstCall/ -- Cordis Corporation today announced plans to extend its current research and development operations by establishing a unique innovation center in the Bay Area of northern California. With an entrepreneurial culture and environment, the center will allow engineers and other researchers to strive for innovative new products quickly and efficiently within state-of-the-art facilities.

The company's newly appointed Chief Technology Officer Campbell Rogers, M.D., will be responsible for the center and direct its strategic planning.

"We are thrilled by the opportunities on the West Coast to extend our research and development capabilities under the leadership of Dr. Rogers, our new Chief Technology Officer" said Rick Anderson, Company Group Chairman, Johnson & Johnson, and Worldwide Franchise Chairman, Cordis Corporation. "The Silicon Valley is known worldwide as a hub of innovative ideas and engineering talent. This is the ideal place to advance our leadership position in the development of innovative products designed to treat the millions of patients with coronary artery and vascular diseases."

The establishment of the company's cardiovascular devices innovative center in the Silicon Valley also provides the company with the opportunity to collaborate with talent from other Johnson & Johnson medical device companies in Northern California including Nitinol Devices and Components and LuMend, Inc., which was recently acquired by Cordis Corporation.

One of the unique aspects of the center will be its focus on customer needs and partnering with them to achieve breakthrough products and offerings.

"Cordis has been a leader in innovation for years and it will be a pleasure to work with the talented researchers and senior leadership there for the next wave of innovative products," said David Williams, M.D., Professor of Medicine, Brown Medical School and Director, Cardiovascular Laboratory and Interventional Cardiology, Rhode Island Hospital, Providence, RI. "As physicians in the cardiac and vascular fields, we share Cordis' aspiration to defeat cardiovascular disease and working together, we are one step closer to this goal."

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease.

CONTACT: Christopher Allman of Cordis Cardiology, +1-786-313-2303, mobile:+1-305-586-6024, Callman1@crdus.jnj.com, or Todd Ringler of Edelman PublicRelations, +1-212-704-4572, mobile: +1-617-872-1235,todd.ringler@edelman.com

Web site: http://www.cordis.com/